<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="185">
  <stage>Registered</stage>
  <submitdate>12/08/2005</submitdate>
  <approvaldate>11/11/2005</approvaldate>
  <actrnumber>ACTRN12605000728639</actrnumber>
  <trial_identification>
    <studytitle>Does tiotropium bromide lead to bronchodilation in cystic fibrosis ?</studytitle>
    <scientifictitle>Does tiotropium bromide lead to bronchodilation in cystic fibrosis ?</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Cystic fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A single dose of inhaled tiotropium bromide with measurement of FEV1 over the following 24 hours.  Then a 7 day 'washout' period follwed by cross-over to the alternate study arm and repeat</interventions>
    <comparator>Placebo with measurement of FEV1 over the following 24 hours.  Then a 7 day 'washout' period follwed by cross-over to the alternate study arm and repeat</comparator>
    <control>Placebo</control>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Improvement in FEV1 by 10% or greater at any time within 24 hours of medication administration</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Symptom improvement</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Medication side-effects</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Confirmed CF, stable disease ( no infective exacerbation for prior 2 weeks ).</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Recent infective exacerbation in prior 2 weeks, pregnant/breastfeeding.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Blinded by means of a sealed envelope with allocation performed by a hospital pharmacist not otherwise involve in the trial conduct</concealment>
    <sequence>Computer generated block randomization</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/07/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>14</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Mater Adults Hospital, South Brisbane</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Greg Keir</name>
      <address>Mater Adults Hospital
Raymond Terrace
South Brisbane QLD 4101</address>
      <phone>+61 7 3240 2111</phone>
      <fax />
      <email>greg_keir@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Greg Keir</name>
      <address>Mater Adults Hospital
Raymond Terrace
South Brisbane QLD 4101</address>
      <phone>+61 7 3240 2111</phone>
      <fax />
      <email>greg_keir@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>